Faslodex (chemical name: fulvestrant) by Astra Zeneca is approved by the U.S. Food and Drug Administration to treat:
postmenopausal women diagnosed with advanced (metastatic) hormone-receptor-positive breast cancer that has stopped responding to other hormonal therapy medicines, such as tamoxifen
Faslodex is the only ERD available to treat breast cancer.
Faslodex won’t work on hormone-receptor-negative breast cancer.
Faslodex is liquid that is given once a month as an injection into a muscle, usually at your doctor’s office. Women usually get Faslodex as long as it is effectively treating the cancer.
Benefits of Faslodex
Research has shown that Faslodex works as well as or better than Arimidex (chemical name: anastrozole), an aromatase inhibitor, in slowing or stopping the growth of metastatic (breast cancer that has spread to other parts of the body), hormone-receptor-positive breast cancer in postmenopausal women after tamoxifen has stopped working.